U6atac-Targeting Nucleic Acid Agents for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for advanced and therapy-resistant prostate cancer, such as castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC), are limited by the development of resistance and the lack of effective markers for early detection, with minor spliceosome (MiS) activity being poorly understood in cancer progression.
Innovation Solution
A pharmaceutical nucleic acid agent targeting snRNA U6atac is developed to inhibit MiS activity, offering a novel therapeutic approach for blocking cancer cell proliferation and serving as a diagnostic marker for cancer, particularly for advanced and therapy-resistant phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments such as castration-resistant prostate cancer therapy are used, then cancer progression is temporarily controlled, but resistance develops and treatment effectiveness is lost
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism of minor spliceosome activity in cancer cells. By using nucleic acid agents that specifically bind to and inhibit minor spliceosome components, the treatment directly addresses the underlying molecular driver of cancer progression and resistance, rather than relying on systemic therapies that eventually fail due to heterogeneous resistance mechanisms.
Solution Approach 2:
The patent changes the therapeutic parameter from targeting androgen receptor pathways to targeting minor spliceosome activity. This parameter change allows for a fundamentally different mechanism of action that bypasses the androgen receptor resistance pathways, thereby extending the duration of treatment response and improving reliability in CRPC and NEPC.
2Loss of information
If minor spliceosome activity is not monitored, then cancer progression mechanisms remain unknown, but diagnostic accuracy and early detection capability are limited
Solution Approach 1:
The patent introduces U6atac snRNA as an intermediary marker that mediates between minor spliceosome activity and detectable diagnostic signals. By measuring U6atac expression levels, the patent provides a precise quantifiable marker for minor spliceosome activity, enabling both early detection and monitoring of treatment response with high measurement precision.
Solution Approach 2:
The patent replaces traditional mechanical or anatomical diagnostic methods with molecular-level detection of U6atac snRNA expression. This substitution enables precise measurement of minor spliceosome activity as a biomarker, providing early detection capability and detailed information about cancer progression mechanisms at the molecular level.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MiS inhibition agent effectively reduces cancer cell proliferation and provides a high likelihood of cancer diagnosis based on U6atac expression levels, demonstrating potential as a therapeutic strategy for lethal prostate cancer and extending to other cancer types.
Implementation Method 1
capable of downregulating or inhibiting the activity of the minor spliceosome (MiS)
Data Source
AI summary
The present invention relates to a pharmaceutical nucleic acid agent capable of downregulating or inhibiting the activity of the minor spliceosome (MiS) for use in treatment or prevention of recurrence of cancer. The invention also relates to a method for the diagnosis of cancer.